Commonwealth Equity Services LLC Makes New $354,000 Investment in Masimo Co. (NASDAQ:MASI)

Commonwealth Equity Services LLC acquired a new stake in Masimo Co. (NASDAQ:MASI - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,139 shares of the medical equipment provider's stock, valued at approximately $354,000.

A number of other institutional investors have also recently made changes to their positions in MASI. Smartleaf Asset Management LLC increased its position in shares of Masimo by 31.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 60 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock valued at $37,000 after buying an additional 64 shares during the last quarter. Blue Trust Inc. raised its stake in Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after buying an additional 71 shares in the last quarter. CIBC Asset Management Inc lifted its holdings in Masimo by 5.6% during the 4th quarter. CIBC Asset Management Inc now owns 1,631 shares of the medical equipment provider's stock worth $270,000 after buying an additional 87 shares during the last quarter. Finally, MML Investors Services LLC boosted its position in shares of Masimo by 4.9% during the 3rd quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider's stock worth $274,000 after acquiring an additional 96 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Remove Ads

Masimo Stock Performance

Masimo stock traded up $2.41 during midday trading on Friday, hitting $153.90. 729,386 shares of the company's stock were exchanged, compared to its average volume of 655,434. The firm's 50 day simple moving average is $170.60 and its 200 day simple moving average is $164.27. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The stock has a market cap of $8.32 billion, a price-to-earnings ratio of 106.14 and a beta of 1.28.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million. Equities research analysts predict that Masimo Co. will post 4.1 EPS for the current year.

Insider Buying and Selling

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Craig B. Reynolds sold 2,053 shares of the business's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the sale, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 9.70% of the company's stock.

Wall Street Analysts Forecast Growth

MASI has been the topic of several research analyst reports. Raymond James raised their target price on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research report on Friday, December 27th. Wells Fargo & Company upped their target price on shares of Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Thursday. Finally, Piper Sandler upped their price objective on shares of Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $194.80.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.